This is an ancillary study using samples collected in the ProBioRIS cohort (NCT06395662). The aim of the project is to highlight new biomarker candidates to assess the risk of conversion to clinically definite multiple sclerosis (CDMS) and disease activity (Evidence of Disease Activity) by taking into account demographic, clinical and MRI parameters. A cohort of healthy subjects will be integrated into the study to serve as a control population. We will study a panel of serum immunoglobulins targeting different Epstein Barr virus antigens to identify latency or reactivation phases. Identifying and prioritizing risk factors for clinical conversion to MS in radiologically isolated syndrome patients is of major importance for the implementation of personalized monitoring and treatment strategies, especially following the recent highlighting of the benefit of background treatments in patients at high risk of CDMS.
Study Type
OBSERVATIONAL
Enrollment
110
Search for EBV seropositivity using SIMAO assay
CHU de Nîmes
Nîmes, France
Prevalence of EBV seropositivity in RIS patients
Measured by single-molecule array (SIMOA)
Time frame: Baseline
Serum vitamin D levels in patients with RIS
Measured with mass spectrometry
Time frame: Baseline
Disease activity in patients with RIS
Evidence of disease aftivity versus no evidence of disease activity
Time frame: Baseline
Prevalence of EBV seropositivity in healthy controls
Measured by single-molecule array (SIMOA)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.